Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease

An unresolved question for the understanding of Alzheimer's disease (AD) pathophysiology is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals do not develop detectable downstream tau pathology and, consequently, clinical deterioration. In vitro evidence suggests that reactive astrocytes unleash Aβ effects in pathological tau phosphorylation. Here, in a biomarker study across three cohorts (n = 1,016), we tested whether astrocyte reactivity modulates the association of Aβ with tau phosphorylation in CU individuals. We found that Aβ was associated with increased plasma phosphorylated tau only in individuals positive for astrocyte reactivity (Ast+). Cross-sectional and longitudinal tau-positron emission tomography analyses revealed an AD-like pattern of tau tangle accumulation as a function of Aβ only in CU Ast+ individuals. Our findings suggest astrocyte reactivity as an important upstream event linking Aβ with initial tau pathology, which may have implications for the biological definition of preclinical AD and for selecting CU individuals for clinical trials

AI is a viable alternative to high throughput screening: a 318-target study

: High throughput screening (HTS) is routinely used to identify bioactive small molecules. This requires physical compounds, which limits coverage of accessible chemical space. Computational approaches combined with vast on-demand chemical libraries can access far greater chemical space, provided that the predictive accuracy is sufficient to identify useful molecules. Through the largest and most diverse virtual HTS campaign reported to date, comprising 318 individual projects, we demonstrate that our AtomNet® convolutional neural network successfully finds novel hits across every major therapeutic area and protein class. We address historical limitations of computational screening by demonstrating success for target proteins without known binders, high-quality X-ray crystal structures, or manual cherry-picking of compounds. We show that the molecules selected by the AtomNet® model are novel drug-like scaffolds rather than minor modifications to known bioactive compounds. Our empirical results suggest that computational methods can substantially replace HTS as the first step of small-molecule drug discovery

Zero Thermal Expansion in ZrMgMo₃O₁₂: NMR Crystallography Reveals Origins of Thermoelastic Properties

The coefficient of thermal expansion of ZrMgMo₃O₁₂ has been measured and was found to be extremely close to zero over a wide temperature range including room temperature (αl = (1.6 ± 0.2) × 10^–7 K^–1 from 25 to 450 °C by X-ray diffraction (XRD)). ZrMgMo₃O₁₂ belongs to the family of AMgM₃O₁₂ materials, for which coefficients of thermal expansion have previously been reported to range from low-positive to low-negative. However, the low thermal expansion property had not previously been explained because atomic position information was not available for any members of this family of materials. We determined the structure of ZrMgMo₃O₁₂ by nuclear magnetic resonance (NMR) crystallography, using ⁹¹Zr, ²⁵Mg, ⁹⁵Mo, and ¹⁷O magic angle spinning (MAS) and ¹⁷O multiple quantum MAS (MQMAS) NMR in conjunction with XRD and density functional theory calculations. The resulting structure was of sufficient detail that the observed zero thermal expansion could be explained using quantitative measures of the properties of the coordination polyhedra. We also found that ZrMgMo₃O₁₂ shows significant ionic conductivity, a property that is also related to its structure